Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 2749

1.

Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes.

Harrison SL, Lane DA, Lip GYH.

Eur J Heart Fail. 2019 Dec 9. doi: 10.1002/ejhf.1685. [Epub ahead of print] No abstract available.

PMID:
31820530
2.

Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage.

Lee SR, Choi EK, Kwon S, Jung JH, Han KD, Cha MJ, Oh S, Lip GYH.

Stroke. 2019 Dec 9:STROKEAHA119028030. doi: 10.1161/STROKEAHA.119.028030. [Epub ahead of print]

PMID:
31813363
3.

Thromboembolic risks associated with paroxysmal and persistent atrial fibrillation in Asian patients: a report from the Chinese atrial fibrillation registry.

Wang Y, Ma CS, Du X, He L, Li J, Wang GH, Wen D, Dong JZ, Pan JH, Lip GYH.

BMC Cardiovasc Disord. 2019 Nov 27;19(1):283. doi: 10.1186/s12872-019-1260-7.

4.

Comparing the Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin in the Elderly Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study.

Chao TF, Chiang CE, Liao JN, Chen TJ, Lip GYH, Chen SA.

Chest. 2019 Dec 3. pii: S0012-3692(19)34383-1. doi: 10.1016/j.chest.2019.11.025. [Epub ahead of print]

PMID:
31809694
5.

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.

Maeng M, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP; RE-DUAL PCI Steering Committee and Investigators.

JACC Cardiovasc Interv. 2019 Dec 9;12(23):2346-2355. doi: 10.1016/j.jcin.2019.07.059.

6.

Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.

Ten Berg JM, de Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung KB, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators.

JACC Cardiovasc Interv. 2019 Dec 9;12(23):2331-2341. doi: 10.1016/j.jcin.2019.08.039.

PMID:
31806214
7.

Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.

Mazurek M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Paquette M, Zint K, França LR, Lu S, Bartels DB, Huisman MV, Lip GYH; GLORIA-AF Investigators.

Am Heart J. 2019 Dec;218:123-127. doi: 10.1016/j.ahj.2019.08.012.

PMID:
31806087
8.

Fluctuating renal function and the risk of incident atrial fibrillation: a nationwide population-based study.

Kwon S, Lee SR, Choi EK, Han KD, Yang S, Lee SY, Lee HJ, Moon I, Lee E, Cha MJ, Lim WH, Oh S, Lip GYH.

Sci Rep. 2019 Dec 2;9(1):18055. doi: 10.1038/s41598-019-54528-w.

9.

Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry.

Paquette M, França LR, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Olshansky B, Huisman MV, Lip GYH, Nieuwlaat R.

Am J Cardiol. 2019 Nov 7. pii: S0002-9149(19)31234-2. doi: 10.1016/j.amjcard.2019.10.047. [Epub ahead of print]

PMID:
31785775
10.

Cognitive Decline Over Time in Patients With Systolic Heart Failure: Insights From WARCEF.

Lee TC, Qian M, Liu Y, Graham S, Mann DL, Nakanishi K, Teerlink JR, Lip GYH, Freudenberger RS, Sacco RL, Mohr JP, Labovitz AJ, Ponikowski P, Lok DJ, Matsumoto K, Estol C, Anker SD, Pullicino PM, Buchsbaum R, Levin B, Thompson JLP, Homma S, Di Tullio MR; WARCEF Investigators.

JACC Heart Fail. 2019 Dec;7(12):1042-1053. doi: 10.1016/j.jchf.2019.09.003.

PMID:
31779926
11.

Thrombotic Profile and Oral Anticoagulation in Asian and Non-Asian Patients With Nonvalvular Atrial Fibrillation.

Gue YX, Inoue N, Spinthakis N, Takei A, Takahara H, Otsui K, Lip GYH, Gorog DA.

J Am Coll Cardiol. 2019 Dec 3;74(22):2822-2824. doi: 10.1016/j.jacc.2019.01.079. No abstract available.

PMID:
31779799
12.

Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin in Atrial Fibrillation Patients with Concomitant Peripheral Artery Disease.

Lee HF, See LC, Li PR, Liu JR, Chao TF, Chang SH, Wu LS, Yeh YH, Kuo CT, Chan YH, Lip GYH.

Eur Heart J Cardiovasc Pharmacother. 2019 Nov 28. pii: pvz072. doi: 10.1093/ehjcvp/pvz072. [Epub ahead of print]

PMID:
31778146
13.

Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish nationwide cohort.

Nielsen PB, Larsen TB, Skjøth F, Søgaard M, Lip GYH.

Eur Heart J Cardiovasc Pharmacother. 2019 Nov 27. pii: pvz070. doi: 10.1093/ehjcvp/pvz070. [Epub ahead of print]

PMID:
31774504
14.

Revisiting the Dynamic Risks of Incident Atrial Fibrillation: Does the Use of Nonsteroidal Anti-Inflammatory Drugs Contribute to Risk?

Harrison SL, O'Flaherty M, Lip GYH.

QJM. 2019 Nov 26. pii: hcz310. doi: 10.1093/qjmed/hcz310. [Epub ahead of print] No abstract available.

PMID:
31769849
15.

Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries.

Tilz RR, Dagres N, Arbelo E, Blomström-Lundqvist C, Crijns HJ, Kirchhof P, Kautzner J, Temporelli PL, Laroche C, Roberts PR, Pehrson S, Lip GYH, Brugada J, Tavazzi L.

Europace. 2019 Nov 26. pii: euz291. doi: 10.1093/europace/euz291. [Epub ahead of print]

PMID:
31768523
16.

Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration.

Schnabel RB, Haeusler KG, Healey JS, Freedman B, Boriani G, Brachmann J, Brandes A, Bustamante A, Casadei B, Crijns HJGM, Doehner W, Engström G, Fauchier L, Friberg L, Gladstone DJ, Glotzer TV, Goto S, Hankey GJ, Harbison JA, Hobbs FDR, Johnson LSB, Kamel H, Kirchhof P, Korompoki E, Krieger DW, Lip GYH, Løchen ML, Mairesse GH, Montaner J, Neubeck L, Ntaios G, Piccini JP, Potpara TS, Quinn TJ, Reiffel JA, Ribeiro ALP, Rienstra M, Rosenqvist M, Sakis T, Sinner MF, Svendsen JH, Van Gelder IC, Wachter R, Wijeratne T, Yan B.

Circulation. 2019 Nov 26;140(22):1834-1850. doi: 10.1161/CIRCULATIONAHA.119.040267. Epub 2019 Nov 25.

PMID:
31765261
17.

Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis.

Chan YH, Lee HF, Chao TF, Wu CT, Chang SH, Yeh YH, See LC, Kuo CT, Chu PH, Wang CL, Lip GYH.

Cardiovasc Drugs Ther. 2019 Nov 19. doi: 10.1007/s10557-019-06910-z. [Epub ahead of print] Review.

PMID:
31745687
18.

Sex Differences in Presentation, Quality of Life, and Treatment in Chinese Atrial Fibrillation Patients: Insights from the China Atrial Fibrillation Registry Study.

Li YM, Jiang C, He L, Li XX, Hou XX, Chang SS, Lip GYH, Du X, Dong JZ, Ma CS.

Med Sci Monit. 2019 Oct 25;25:8011-8018. doi: 10.12659/MSM.919366.

19.

Atrial Fibrillation in Heart Failure: Focus on Antithrombotic Management.

Obeidat M, Burgess M, Lip GYH.

Heart Fail Clin. 2020 Jan;16(1):107-120. doi: 10.1016/j.hfc.2019.08.007. Review.

PMID:
31735308
20.

'Real-world' observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS).

Torp-Pedersen C, Goette A, Nielsen PB, Potpara T, Fauchier L, John Camm A, Arbelo E, Boriani G, Skjoeth F, Rumsfeld J, Masoudi F, Guo Y, Joung B, Refaat MM, Kim YH, Albert CM, Piccini J, Avezum A, Lip GYH; ESC Scientific Document Group .

Europace. 2019 Nov 14. pii: euz210. doi: 10.1093/europace/euz210. [Epub ahead of print]

PMID:
31725156
21.

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis.

Xiong Q, Wang C, Liu H, Tan Z, Chen C, Li J, Lip GYH, Hong K.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619885188. doi: 10.1177/1076029619885188.

PMID:
31718263
22.

Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study).

Lip GYH, Skjøth F, Nielsen PB, Larsen TB.

Am J Cardiol. 2019 Oct 10. pii: S0002-9149(19)31103-8. doi: 10.1016/j.amjcard.2019.09.034. [Epub ahead of print]

PMID:
31711634
23.

Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.

Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM.

Circ Cardiovasc Interv. 2019 Nov;12(11):e008160. doi: 10.1161/CIRCINTERVENTIONS.119.008160. Epub 2019 Nov 11.

PMID:
31707805
24.

Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation.

Huppertz N, Lip GYH, Lane DA.

Clin Res Cardiol. 2019 Nov 7. doi: 10.1007/s00392-019-01567-y. [Epub ahead of print]

PMID:
31701215
25.

Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range.

Lip GYH, Bhatt DL, Hohnloser SH, Kimura T, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Cannon CP.

J Am Coll Cardiol. 2019 Nov 12;74(19):2431-2433. doi: 10.1016/j.jacc.2019.09.009. No abstract available.

PMID:
31699285
26.

Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries.

Miyazawa K, Ogawa H, Mazurek M, Shantsila E, Lane DA, Wolff A, Akao M, Lip GYH.

Circ J. 2019 Nov 25;83(12):2434-2442. doi: 10.1253/circj.CJ-19-0546. Epub 2019 Nov 6.

27.

Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management.

Gumprecht J, Domek M, Lip GYH, Shantsila A.

J Hum Hypertens. 2019 Nov 5. doi: 10.1038/s41371-019-0279-7. [Epub ahead of print] Review.

PMID:
31690818
28.

Prevalence of Hypertension in the Middle Belt of Ghana: A Community-Based Screening Study.

Dosoo DK, Nyame S, Enuameh Y, Ayetey H, Danwonno H, Twumasi M, Tabiri C, Gyaase S, Lip GYH, Owusu-Agyei S, Asante KP.

Int J Hypertens. 2019 Oct 7;2019:1089578. doi: 10.1155/2019/1089578. eCollection 2019.

29.

Reply: Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Liver Disease.

Choi EK, Lee SR, Oh S, Lip GYH.

J Am Coll Cardiol. 2019 Nov 5;74(18):2330-2331. doi: 10.1016/j.jacc.2019.09.003. No abstract available.

PMID:
31672195
30.

A Time to Stop and Think Before the Shock.

Mandrola J, Lip GYH, Foy A.

J Am Coll Cardiol. 2019 Nov 5;74(18):2275-2277. doi: 10.1016/j.jacc.2019.08.1044. No abstract available.

PMID:
31672184
31.

Comparison of Risk Scores for the Prediction of the Overall Cardiovascular Risk in Patients with Ischemic Stroke: The Athens Stroke Registry.

Georgiopoulos G, Ntaios G, Stamatelopoulos K, Manios E, Korompoki E, Vemmou E, Milionis H, Masi S, Lip GYH, Vemmos K.

J Stroke Cerebrovasc Dis. 2019 Dec;28(12):104415. doi: 10.1016/j.jstrokecerebrovasdis.2019.104415. Epub 2019 Oct 25.

PMID:
31669071
32.

Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use.

Proietti M, Marzona I, Vannini T, Tettamanti M, Fortino I, Merlino L, Basili S, Mannucci PM, Boriani G, Lip GYH, Roncaglioni MC, Nobili A.

Mayo Clin Proc. 2019 Dec;94(12):2427-2436. doi: 10.1016/j.mayocp.2019.06.012. Epub 2019 Oct 23.

PMID:
31668449
33.

Identification of Markers Associated With Development of Stroke in "Clinically Low-Risk" Atrial Fibrillation Patients.

Shin SY, Han SJ, Kim JS, Im SI, Shim J, Ahn J, Lee EM, Park YM, Kim JH, Lip GYH, Lim HE.

J Am Heart Assoc. 2019 Nov 5;8(21):e012697. doi: 10.1161/JAHA.119.012697. Epub 2019 Oct 31.

34.

Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme.

Mazurek M, Halperin JL, Huisman MV, Diener HC, Dubner SJ, Ma CS, Rothman KJ, Healey JS, Teutsch C, Paquette M, França LR, Lu S, Bartels DB, Lip GYH.

Europace. 2019 Oct 25. pii: euz278. doi: 10.1093/europace/euz278. [Epub ahead of print]

PMID:
31651951
35.

Malignant hypertension: does this still exist?

Domek M, Gumprecht J, Lip GYH, Shantsila A.

J Hum Hypertens. 2019 Oct 21. doi: 10.1038/s41371-019-0267-y. [Epub ahead of print] No abstract available.

PMID:
31636349
36.

Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group.

Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, Leontiadis GI, Abraham NS, Calvet X, Chan FKL, Douketis J, Enns R, Gralnek IM, Jairath V, Jensen D, Lau J, Lip GYH, Loffroy R, Maluf-Filho F, Meltzer AC, Reddy N, Saltzman JR, Marshall JK, Bardou M.

Ann Intern Med. 2019 Oct 22. doi: 10.7326/M19-1795. [Epub ahead of print]

PMID:
31634917
37.

Prevalence and Associated Stroke Risk of Human Immunodeficiency Virus-Infected Patients With Atrial Fibrillation - A Nationwide Cohort Study.

Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, Lip GYH, Joung B.

Circ J. 2019 Nov 25;83(12):2547-2554. doi: 10.1253/circj.CJ-19-0527. Epub 2019 Oct 17.

38.

Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) Registry.

Bikdeli B, Jiménez D, Garcia-Tsao G, Barba R, Font C, Díaz-Pedroche MDC, Mazzolai L, Little DHW, Tufano A, Tafur AJ, Siegal D, Lip GYH, Monreal M; RIETE Investigators.

Semin Thromb Hemost. 2019 Nov;45(8):793-801. doi: 10.1055/s-0039-1697682. Epub 2019 Oct 15.

PMID:
31614388
39.

Assessment of Arterial Stiffness in Patients with Resistant Hypertension: Additional Insights into the Pathophysiology of this condition?

Alsharari R, Lip GYH, Shantsila A.

Am J Hypertens. 2019 Oct 14. pii: hpz169. doi: 10.1093/ajh/hpz169. [Epub ahead of print]

PMID:
31608357
40.

Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.

Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, Collet JP, Valgimigli M, Heidbuchel H, Lip GYH.

Europace. 2019 Oct 11. pii: euz259. doi: 10.1093/europace/euz259. [Epub ahead of print]

PMID:
31603196
41.

Should We Judge Stroke Risk by Static or Dynamic Risk Scores? A Focus on the Dynamic Nature of Stroke and Bleeding Risks in Patients With Atrial Fibrillation.

Domek M, Gumprecht J, Mazurek M, Chao TF, Lip GYH.

J Cardiovasc Pharmacol. 2019 Dec;74(6):491-498. doi: 10.1097/FJC.0000000000000750.

PMID:
31599783
42.

Prevalence of modifiable risk factors and relation to stroke and death in patients with atrial fibrillation: A report from the China atrial fibrillation registry study.

Jiang C, Lan DH, Du X, Geng YP, Chang SS, Zheng D, Chen JB, Yu RH, Sang CH, Long DY, Tang RB, Zhou YC, Min Y, Lu Y, Dong JZ, Lip GYH, Ma CS.

J Cardiovasc Electrophysiol. 2019 Dec;30(12):2759-2766. doi: 10.1111/jce.14231. Epub 2019 Oct 17.

PMID:
31599040
43.

The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients.

Kim D, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, Lip GYH, Joung B.

Europace. 2019 Oct 10. pii: euz273. doi: 10.1093/europace/euz273. [Epub ahead of print]

PMID:
31598651
44.

Breaking the rules for studies using real-world observational data: The case of direct-acting anticoagulants and antiepileptic drugs.

Brown J, Cicali B, Pham P, Schmidt S, Lip GYH.

Eur Heart J Cardiovasc Pharmacother. 2019 Oct 8. pii: pvz053. doi: 10.1093/ehjcvp/pvz053. [Epub ahead of print] No abstract available.

PMID:
31593242
45.

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease.

Moon I, Lee SR, Choi EK, Lee E, Jung JH, Han KD, Cha MJ, Oh S, Lip GYH.

J Clin Med. 2019 Oct 4;8(10). pii: E1624. doi: 10.3390/jcm8101624.

46.

Bodyweight fluctuation is associated with increased risk of incident atrial fibrillation.

Lee HJ, Choi EK, Han KD, Lee E, Moon I, Lee SR, Cha MJ, Oh S, Lip GYH.

Heart Rhythm. 2019 Oct 1. pii: S1547-5271(19)30904-X. doi: 10.1016/j.hrthm.2019.09.029. [Epub ahead of print]

PMID:
31585180
47.

C9orf72 and intracerebral hemorrhage.

Hostettler IC, Bernal-Quiros M, Wong A, Sharma N, Wilson D, Seiffge DJ, Shakeshaft C, Jäger HR, Cohen H, Yousry T, Al-Shahi Salman R, Lip GYH, Brown MM, Muir KW, Werring DJ, Houlden H; CROMIS-2 collaborators.

Neurobiol Aging. 2019 Jul 18. pii: S0197-4580(19)30209-X. doi: 10.1016/j.neurobiolaging.2019.07.007. [Epub ahead of print]

PMID:
31582231
48.

A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention.

Gumprecht J, Domek M, Lip GYH.

Expert Opin Drug Saf. 2019 Dec;18(12):1119-1125. doi: 10.1080/14740338.2019.1676723. Epub 2019 Oct 8.

PMID:
31580164
49.

Meeting the unmet needs to improve management and outcomes of patients with atrial fibrillation: fitting global solutions to local settings.

Potpara TS, Mujovic N, Lip GYH.

Pol Arch Intern Med. 2019 Sep 30;129(9):574-576. doi: 10.20452/pamw.14996. Epub 2019 Sep 30. No abstract available.

50.

Heart rate variability in atrial fibrillation: The balance between sympathetic and parasympathetic nervous system.

Khan AA, Lip GYH, Shantsila A.

Eur J Clin Invest. 2019 Nov;49(11):e13174. doi: 10.1111/eci.13174. Review.

PMID:
31560809

Supplemental Content

Support Center